Noxxon Pharma, AG: Series D $40M

Posted in I - Series D, Q - 2Q10, R - INTERNATIONAL, X - Aptamer, X - Hematology, X - Inflammation

Noxxon Pharma (Germany) a clinical-stage biopharmaceutical company focused on the development of aptamers for the treatment of inflammation and hematological indications closed a $40M Series D financing. Participants include NGN Capital, TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, Seventure Partners, VC Fonds Technologie Berlin, Dow Venture Capital, Fcp Medical BioHealth-Trends, IBG Beteiligungsgesellschaft Sachsen-Anhalt [...]

Sep

2009

aTyr Pharma, Inc.: Series C $12M

Posted in I - Series C, Q - 3Q09, R - WEST, X - Autoimmune, X - Hematology, X - Inflammation, X - Metabolism, XX - CA

aTyr Pharma (San Diego, CA) a preclinical-stage biopharmaceutical company focused on inflammation, autoimmune, hematopoietic and metabolic disorders, closed a $12M Series C financing. Participants include Alta Partners, Cardinal Partners and Polaris Ventures.

Dec

2008

Quotient Bioscience Group, Ltd.: Series B $53M

Posted in I - Series B, Q - 3Q08, R - INTERNATIONAL, X - Diagnostic, X - Hematology

Quotient Bioscience Group (United Kingdom) a provider of bioscience analytics and safety evaluation services, closed a $53M Series B financing. Participants include TA Associates.

to top of page...